Animal / preclinical evidence · 5-Amino-1MQ
5A1MQ metabolic effects in diet-induced obese mice
5A1MQ dose-dependently limited weight/fat gain and improved glucose/insulin and liver measures in mice.
Quick read
Animal / preclinical evidence
What this study tells us
This was preclinical research in animals and/or laboratory models. It can show a biological signal, but it cannot prove the same benefit, dose or safety in people.
Who was studied?
Diet-induced obese mice
How many?
Animal or laboratory sample size is not captured in this public summary.
What happened?
5A1MQ dose-dependently limited weight/fat gain and improved glucose/insulin and liver measures in mice.
What stops us overclaiming?
Preclinical only; therapeutic window and chronic toxicity in people remain unknown.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
5A1MQ dose-dependently limited weight/fat gain and improved glucose/insulin and liver measures in mice.
Study details
Study designPreclinical animal PK/efficacy study
PopulationDiet-induced obese mice
RouteOral / IV / subcutaneous PK in mice; daily treatment arm
Regimen / exposureOnce daily for 28 days in efficacy arm
Duration28 days
ComparatorVehicle
Primary endpoint / questionBody composition, glucose/insulin and liver pathology
Safety resultNo human safety information generated.
Key limitationsPreclinical only; therapeutic window and chronic toxicity in people remain unknown.
Registry / identifierPMID 39161060